New drug tested for chronic Graft-Versus-Host disease in india
NCT ID NCT07135973
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have tried at least two prior treatments. The study lasts up to 12 months, with 24 weeks of treatment and 7 clinic visits, focusing on side effects and how well the disease responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.